Today: 21 May 2026
FTSE 100 Forecast 2026: UK Stock Market Pulls Back From Records as Oil Slides
7 January 2026
2 mins read

FTSE 100 Forecast 2026: UK Stock Market Pulls Back From Records as Oil Slides

London, Jan 7, 2026, 10:52 GMT — Regular session

UK shares slipped on Wednesday, with the FTSE 100 down 0.7% at 10,054.34 points by 1052 GMT. BP and several miners were among the heaviest drags after the benchmark’s recent run of records.

The index only logged its first close above 10,000 on Monday at 10,004.57, led by precious-metal miners and defence stocks after the U.S. capture of Venezuelan President Nicolas Maduro. The UK stock market forecast for 2026 now hinges on whether that geopolitical bid and expectations of Bank of England easing can outlast swings in oil and risk appetite.

The Bank Rate, the Bank of England’s key interest rate, stands at 3.75% and the next policy decision is due on Feb. 5. For the FTSE 250, which is more tied to the domestic economy, a turn in rate expectations can matter as much as earnings.

Oil moved back into focus after U.S. President Donald Trump said Washington had struck a deal to import $2 billion worth of Venezuelan crude, which investors expected to increase supplies. Shell fell 2.4% and BP slid 3.1% by 0920 GMT, dragging the European energy sector lower. “Even if momentum sometimes breaks, markets are premised on an operating environment that is supportive,” said Richard Flax, chief investment officer at Moneyfarm. Reuters

Brent fell 0.6% to $60.35 a barrel by 0928 GMT and U.S. WTI was down 0.9% at $56.61, extending the previous session’s declines. UBS analyst Giovanni Staunovo said the Trump post put “downward pressure” on crude earlier, while Morgan Stanley has estimated the market could tip into a surplus of as much as 3 million barrels per day in the first half of 2026. Reuters

UK data underscored the fragile backdrop: the S&P Global/CIPS construction PMI — a survey where readings below 50 signal contraction — came in at 40.1 in December. “Many firms cited subdued demand and fragile client confidence,” said Tim Moore, economics director at S&P Global Market Intelligence. Investing.com

Company news has also steered early-January trading. The FTSE 100 hit a record close on Tuesday after AstraZeneca announced a strategic collaboration with BostonGene, while Next and Ocado jumped on upbeat updates and a weaker pound helped exporters. The FTSE 250 rose 0.9% to its highest in nearly four years.

Next lifted its annual profit outlook for the fifth time after full-price sales rose 10.6% in the nine weeks to Dec. 27, but it warned growth would slow to 4.5% in its 2026/27 year as “pressures on employment” filter through. “This tough backdrop may make future upgrades harder to come by,” said Shore Capital analyst David Hughes. Reuters

Takeovers are another theme investors are tracking for 2026 after years of London-listed firms trading at discounts. Auction Technology said it rejected 11 approaches from its top shareholder FitzWalter Capital; the bids marked the first takeover interest announced in a UK-listed company in 2026.

But Wednesday’s pullback is a reminder that the FTSE’s heavy exposure to commodities can cut both ways if oil stays soft. Markets next turn to retailer updates from Tesco and Marks & Spencer on Thursday and Sainsbury’s on Friday, before official UK inflation data on Jan. 21 provides the next key read on pricing pressure and rate-cut bets.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop